Tumour suppressor candidate 7 (TUSC7) is a novel tumor suppressor gene generating long non-coding RNA (lncRNAs) in several types of human cancers. The expression and function of TUSC7 in human brain glioma has yet to be elucidated. In this study, TUSC7 was poorly expressed in tissues and cell lines of glioma, and the lower expression was correlated with glioma of the worse histological grade. Moreover, TUSC7 is a prognostic biomarker of glioma patients. Up-regulation of TUSC7 suppressed cellular proliferation and invasion of glioma cells, and accelerated cellular apoptosis. Bioinformatics analysis showed that TUSC7 specifically binds to miR-23b. MiR-23b was up-regulated in glioma and negatively correlated with the expression of TUSC7. The miR-23b expression was inhibited remarkably by the upregulation of TUSC7 and the reciprocal inhibition was determined between TUSC7 and miR-23b.RNA pull-down and luciferase reporter assays were used to validate the sequence-specific correlation between miR-23b and TUSC7. TUSC7 inhibited the proliferation, migration and invasion of glioma cells and promoted cellular apoptosis largely bypassing miR-23b. We conclude that the lncRNA TUSC7 acted as a tumor suppressor gene negatively regulated by miR-23b, suggesting a novel therapeutic strategy against gliomas.
INTRODUCTION
Human brain glioma is the most general intracranial tumor, which is characterized by malignant proliferation, chemotherapy resistance, intracranial metastasis, and high-frequency recurrence (Kuhnt et al., 2011; Hu et al., 2016) . The mortality due to glioma is the highest among the nervous system tumors, and the prognosis is poor (Zeng et al., 2015; Chen et al., 2016) . Until now, surgery was indicated as the first-line treatment for gliomas. Chemotherapy and radiotherapy after initial surgical resection are considered effective in preventing recurrence and metastasis (Mrugala, 2013; Alifieris and Trafalis, 2015) . However, chemotherapy and radiotherapy does not work for everyone with glioma, they help about half the people treated (Spinelli et al., 2012; Alexander et al., 2013) . Therefore, the prognosis of patients, especially with high-grade glioma is still poor, despite prompt, and comprehensive treatment. The median survival time of patients with anaplastic astrocytoma is approximately 2-3 years. Among patients with aggressive glioblastomas, the median survival time is nearly 12 to 14.6 months, and the 2-year median survival rate is 30% (Nieder et al., 2008) . Therefore, discovery of new therapeutic strategies and targets against human brain glioma is imperative.
Long non-coding RNA (lncRNA) is a type of endogenous RNA, which is not translated to protein. Over the past several years, studies involving lncRNAs increased rapidly. LncRNAs mediate critical biological events such as cell cycle, autophagy, and apoptosis (Song et al., 2014; Xu et al., 2014; Zhao et al., 2014) . A few lncRNAs show anomalous expression and function in malignant tumors, by acting as oncogenes or tumor suppressor genes (Modali et al., 2015; Wang X. et al., 2015) .
Tumor suppressor candidate 7 (TUSC7) located at 3q13.31 encodes a lncRNA, which is a potential tumor suppressor in gastric cancer, non-small-cell lung cancer, osteosarcoma and hepatocellular carcinoma (Qi et al., 2015; Cong et al., 2016; . However, nothing is known about the expression level of TUSC7 in glioma or whether it is involved in the gliomagenesis. In our microarray assays, TUSC7 showed greater than 10-fold down-regulation in human brain glioma tissue than in control samples. Detection of low levels of TUSC7 expression in glioma tissues suggested a tumor suppressor role.
In this study, the expression of lncRNA TUSC7 was detected, and its regulatory effects and mechanisms in glioma cells were examined. Our findings facilitated the development of effective clinical interventions targeting human brain gliomas.
MATERIALS AND METHODS

Ethical Approval
All the patients were informed about the purposes of the study and consequently have signed their "consent of the patient." All investigations conformed to the principles outlined in the Declaration of Helsinki and were performed with permission by the responsible Medical Ethics Committees of China Medical University (CMU-2010018) .
Clinical Specimens
A total of 39 glioma and 17 adjacent normal brain tissues (NBT) were obtained from Shengjing Hospital and Affiliated First Hospital of China Medical University from December 2010 to November 2011. The patients were not exposed to radiation or chemotherapy before surgery. The tissue samples were stored in liquid nitrogen immediately after surgery. All the pathological data were assembled according to the 2007 WHO classification. The patients' age (mean ± SD) was 54.1 ± 6.8 years (ranging from 45 to 62 years) including 24 males and 15 females. All glioma patients included nine cases of grade I, 10 cases of grade II, 11 cases of grade III, and nine cases of grade IV, according to pathological diagnosis. This study was approved by the Medical Ethics Committees of China Medical University and the patients provided written informed consent.
Cell Culture
Human brain glioma U251 and U87 cell lines and HEK 293T cells were obtained from China Academy of Chinese Medical Sciences. The cells were cultured in DMEM medium supplemented with 10% fetal bovine serum (Life Technologies Corporation, Carlsbad, CA, USA), and cultured at 37 • C with 5% CO 2 . Primary normal human astrocytes (NHA) were obtained from the Sciencell Research Laboratories (Carlsbad, CA, USA) and cultured in special Astrocyte Basal Medium (CloneticsBioWhittaker) supplemented with 10 µg/mL human epidermal growth factor, 10 mg/mL insulin, 25 µg/mL progesterone, 50 mg/mL transferrin, 50 mg/mL gentamicin, 50 µg/mL amphotericin, and 10% FBS.
Quantitative Real Time-PCR (qRT-PCR)
Total RNA was harvested with TRIzol reagent (Life Technologies Corporation, Carlsbad, CA, USA) and reverse transcribed to cDNA using Reverse-Transcription Kit (Applied Biosystems, USA). The expression of TUSC7 and miR-23b was detected with SYBR (Applied Biosystems, Foster City, CA, USA). The TUSC7 primers were: 5 -TTTATGCTTGAGCCTTGA-3 (sense) and 5 -CTTGCCTGAAATACTTGC-3 (antisense). GAPDH and U6 served as endogenic control genes. The primers of miR23b, GAPDH and U6 were obtained from Genescript Company (Nanjing, China). The C t value of the detected gene varied between 18 and 30, and was quantified using the 2 − Ct method (Song et al., 2014) .
Transfection
The over-expression vector pE-TUSC7 and empty pEGFP-N1 (NC) was obtained from Genescript Company (Nanjing, China). Cells at approximately 60-70% confluence were transfected with Lipofectamine TM 3000 Reagent (Life Technologies Corporation, Carlsbad, CA, USA) according to protocols after 24 h of culture. G418 (Invitrogen, Carlsbad, CA, USA) was used to establish stable cell lines, and qRT-PCR was used to determine the transfection efficiencies. Moreover, miR-23b agonist (agomir23b), miR-23b antagonist (antagomir-23b), and their NC (agomir-NC and antagomir-NC) (Sangon, Shanghai, China) were transfected into U251 and U87 cells, respectively, or cells with TUSC7 over-expression transiently.
Cell Proliferation
U251 and U87 cells (2 × 10 4 /well) were seeded in a 96-well plate at a density of 2000 cells/well. Following addition of 20 µL of 0.5 mg/mL MTT solution (Sigma, USA) to each well, the plate was incubated at 37 • C. After 4 h, the MTT solution was discarded, and 0.2 mL DMSO was added to each well. Before the 96-well plate was analyzed on the SpectraMax M5 microplate reader (Molecular Devices, USA) at 450 nm, it was incubated for 30 min. The cell viability was calculated as follows: (OD value of test group -OD value of blank group)/(OD value of control group -OD value of blank group). Five replicate wells were set up in each group and five independent experiments were conducted repeatedly.
Apoptosis
Apoptosis was assessed using dual-color flow cytometry. Cells were harvested, and apoptosis was detected with Annexin V-FITC apoptosis detection kit (KeyGEN, China) following the manufacturer's protocol. Flow cytometry (BD, USA) and CELLQuest 3.0 software (BD, USA) were used to analyze the data.
Cell Migration and Invasion Assay
Migration and invasion of U251 and U87 cells in vitro were assayed using Transwell chamber (Costar, Corning, NY, USA) with polycarbonic membrane (6.5 mm in diameter, 8 µm pore size). In the migration assay, the transfected cells were resuspended in 100 µL serum-free medium at a density of 5 × 10 5 cells/mL and added in the upper chamber. Six hundred microliters of DMEM/high-glucose or DMEM/F12 medium supplemented with 10% FBS was added to the lower chamber. After incubation for 48 h, the cells on the upper membrane surface were mechanically removed. Cells that had migrated or invaded to the lower side of the membrane were fixed with methanol and stained with 20% Giemsa. Stained cells were counted under a microscope in five randomly chosen fields and the average number was calculated. In the invasion assay, the Transwell membrane was coated with 80 µL of Matrigel solution (500 ng/µL; BD, Franklin Lakes, NJ, USA) and incubated at 37 • C for 4 h, the remaining steps were similar to the migration assay.
Luciferase Reporter Assay
Dual-luciferase reporter plasmids including pmiR-TUSC7-wt (containing miR-23b target binding sequence in TUSC7) and pmiR-MACC1-mut (containing the mutant binding sequence) were constructed by Genescript (Nanjing, China). Luciferase assay was conducted by co-transfecting pmiR-TUSC7-wt or pmiR-MACC1-mut and agomir-23b or agomir-NC into HEK 293T cells. A dual-luciferase reporter assay system (Promega, USA) was used to detect the luciferase activity after cotransfection in HEK 293T cells for 48 h according to the manufacturer's protocol.
RNA Pull-Down Assay
Probes for miR-23b or TUSC7 were biotinylated (Sangon, Shanghai, China) and transfected into glioma cells. Then 48 h later, cells were harvested and lysed. The samples were incubated with Dynabeads M-280 Streptavidin (Invitrogen, Carlsbad, CA, USA). Biotinylated miR-23b was incubated with beads for 10 min, and treated with washing buffer. The bound RNAs were analyzed by qRT-PCR.
RNA Immunoprecipitation (RIP)
RNA Immunoprecipitation experiments were performed using the Magna RIP RNA-Binding Protein IP Kit (Millipore, Bedford, MA, USA) and the Ago2 antibody (2897; Cell Signaling, Danvers, MA, USA) according to the manufacturer's instructions and previous studies . Eventually, purified RNAs in the precipitates were used to determine TUSC7 and miR-23b expression.
Statistical Analysis
Statistical analysis was accomplished with SPSS 13.0 (IBM, Chicago, IL, USA). The data were presented as mean ± SD of three independent experiments and compared using Student's t-test and one-way ANOVA. The association between TUSC7 expression and pathological grade was determined in univariate analysis and binary logistic regression. Overall survival rate was calculated by Kaplan-Meier method with the log-rank test for comparisons. P < 0.05 indicated significant difference.
RESULTS
TUSC7 Down-Regulated in Glioma Specimens and Cell Lines
In our microarray assays, the expression of TUSC7 showed over 10-fold down-regulation in human brain glioma tissue than in control samples (Figure 1 ). TUSC7 expression in glioma samples was significantly lower than in the NBT samples (Figure 2A) . The expression of TUSC7 in U251 and U87 cells was also downregulated compared with the NHA cells (p < 0.05) (Figure 2B ), which provided initial evidence suggesting that the depletion of TUSC7 plays a key role in glioma formation.
The correlation between TUSC7 expression and specific clinical characteristics of glioma indicated that glioma with a worse histological grade showed a tendency to express significantly lower TUSC7 (p < 0.05). However, miR-23b expression was not significantly correlated with other clinical characteristics, such as age, gender and metastasis (p > 0.05).
TUSC7 Acts as a Prognostic Biomarker in Glioma Patients
Interestingly, TUSC7 was found to be a prognostic biomarker in glioma patients. Compared with glioma patients with higher TUSC7 expression, a lower expression of TUSC7 was associated with a remarkably shorter survival time in Kaplan-Meier analysis (Figure 2C) , and a significantly worse prognosis in the univariate Cox proportional hazards regression analysis of overall survival (HR = 2.813, 95% CI: 1.504-6.172; P = 0.017). The results established that down-regulation of TUSC7 plays an important role in the tumorigenesis of glioma. 
Up-Regulation of TUSC7 Inhibits the Malignant Behavior of Glioma Cells
To investigate whether TUSC7 affected the malignant behavior of U251 and U87 cells, cells stably over-expressing TUSC7 were constructed ( Figure 3A) . As shown in Figures 3B,C, TUSC7 over-expression significantly inhibited cell viability and promoted the apoptosis of both U251 and U87 cells when compared with the NC groups (P < 0.05). Over-expression of TUSC7 impeded the migration by roughly 42% in U251 cells and by nearly 45% in U87 cells ( Figure 3D) . A corresponding effect on invasion was also observed in a parallel invasion assay, which showed a significant inhibition of invasion in U251 and U87 cells compared with the respective NC group (P < 0.05).
Reciprocal Inhibition between miR-23b and TUSC7 in Glioma
Bioinformatics analysis was used to search for the potential targeted microRNAs of TUSC7, such as Targetscan, Starbase, and microRNA.org. Together, a miR-23b binding site (1125-1140 bp) was found in TUSC7 transcript, and TUSC7 was a predicted gene of miR-23b ( Figure 4A) . Moreover, Qi et al. (2015) reported a reciprocal regulation between miR-23b and TUSC7 in gastric cancer (Xu et al., 2014) . However, such a regulatory relationship in glioma is still unclear.
As shown in Figure 4B , miR-23b was up-regulated significantly in glioma tissues than that in the normal tissues, showing a negative correlation with TUSC7 in the Pearson's correlation analysis. To establish whether TUSC7 was a target gene of miR-23b, agomir-23b, and antagomir-23b were transfected into U251 and U87 cells. Further, qRT-PCR showed that agomir-23b down-regulated TUSC7 expression and antagomir-23b exhibited the opposite effect in U251 and U87 cells (P < 0.01; Figure 4C) . Moreover, the dual-luciferase reporter assay indicated that the relative luciferase activity was decreased in HEK 293T transfected with wild type vector via enhanced miR-23b expression, and the foregoing inhibition was recovered by Mut vector. These results suggested that TUSC7 was a specific target gene of miR-23b ( Figure 4D) .
Furthermore, the biotin-avidin pull-down assay showed that TUSC7 was pulled down by biotinylated miR-23b (Figure 4E) , but not by biotinylated miR-23b-mut containing mutations in the putative binding site involving TUSC7 and miR-23b. The findings suggested that miR-23b was sequenced specifically and directly bound to TUSC7. Conversely, the biotin-labeled TUSC7 probe was used to demonstrate that TUSC7 was also pulled down by miR-23b ( Figure 4F ). The relative luciferase activities were inhibited in the HEK-293 cells co-transfected with wild-type vector and p agomir-23b, and not with the mutant-type vector. Firefly luciferase activity was normalized to Renilla luciferase. (E) Detection of TUSC7 mRNA using qRT-PCR in the sample pulled down by biotinylated miR-23b. (F) Detection of miR-23b mRNA using qRT-PCR in the sample pulled down by biotinylated TUSC7. (G) MiR-23b expression was down-regulated significantly by TUSC7 over-expression in U251 and U87 cell lines. (H,I) Association of TUSC7 and miR-23b with Ago2 in U251 and U87 cells. Cellular lysates from U251 and U87 cells were used for RIP with antibody against Ago2. TUSC7 and miR-23b expression levels were detected using qRT-PCR.
* P < 0.05.
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The RNA-induced silencing complex (RISC) is a major mechanism of miRNAs to silence target genes, and Ago2 protein is a key constituent of RISC complex. To validate the presence of both miR-23b and TUSC7 in the RISC complex, a RIP experiment was conducted using Ago2 antibody to confirm that both miR23b and TUSC7 were found in the Ago2 pellet (Figures 4H,I ).
Down-Regulation of miR-23b Inhibits the Malignant Behavior of Glioma Cells
The antagomiR-23b-inhibited U251 and U87 cells were used to investigate the malignant behavior of miR-23b. As shown in Figures 5A-C , the viability of cells with miR-23b downregulation decreased significantly, and the apoptotic rate was enhanced remarkably, while the migration and invasion were reduced significantly in both U251 and U87 cells compared with the respective NC groups (P < 0.05).
Up-Regulation of miR-23b Mostly Reversed TUSC7-Induced Regulation of Glioma Cells
Due to the reciprocal inhibition between TUSC7 and miR-23b, the regulatory role of miR-23b remains unclear. Agomir-23b was used to transfect into U251 and U87 cells stably over-expressing TUSC7.
As shown in Figures 6A,B , up-regulated miR-23b largely reversed the inhibitory effect of TUSC7 on cell proliferation, migration, and invasion. Moreover, over-expression of miR23b also substantially suppressed cellular apoptosis promoted by TUSC7 (Figure 6C) . The regulatory effects of TUSC7 on biological behaviors of glioma cells were reversed largely by miR23b. The results indicated that miR-23b regulated the biological behavior of glioma cells via TUSC-7.
DISCUSSION
It is well known that human brain glioma cells are strongly resistant to chemotherapy and radiotherapy, with a low apoptotic ratio and high malignant proliferative ability (Dahlrot, 2014; Lim et al., 2014) . Those features are helpful to cells malignant growth and invasion of glioma, which may be a key factor underlying poor prognosis and recurrence of glioma (Wang F. et al., 2014) .
Recent studies suggest that more than 75% of the human genome can be transcribed to RNA. However, only about 1.2% of those RNAs are translated to proteins. A large proportion of noncoding RNAs might play important and complex physiological and pathological roles (Alaimo et al., 2014) . Recent reports suggest that lncRNAs have a functional role in cell proliferation, apoptosis, autophagy, invasion, and metastasis (Fang et al., 2014;  FIGURE 5 | (A,B) Mir-23b down-regulation inhibited cell viability and advanced apoptosis of U251 and U87 cells. (C) Mir-23b down-regulation disrupted the migration and invasion of U251 and U87 cells, Scale bars represent 100 µm. * P < 0.05 vs. Blank and NC group. FIGURE 6 | Over-expression of miR-23b partly reversed TUSC7-induced inhibition of proliferation (A), migration and invasion (B), and partly reversed TUSC7-induced apoptosis (C) in U251 and U87 cells. Scale bars represent 100 µm. * P < 0.05, * * P < 0.01. Nie et al., 2015) . The functions of a few lncRNAs and their relationship with disease have been established, although many of these genes were screened and identified recently. Intriguingly, increasing evidence suggests that lncRNAs regulate tumorigenesis (Banet et al., 2000; Kraus et al., 2015) .
In order to identify the lncRNA expression profiles in human brain glioma, we used microarray assays together with real-time PCR to screen and identify several lncRNAs with significantly altered expression. Among the lncRNAs, TUSC7 exhibited over 10-fold down-regulation in human brain glioma tissue than in control samples. Subsequently, the down-regulated expression of TUSC7 was confirmed in glioma tissues and cells, and patients with worse histological grade displayed significantly lower TUSC7 expression.
We further explored the effect of TUSC7 on the biological behavior of glioma cells U251 and U87. Our results showed that over-expression of TUSC7 significantly repressed cell proliferation, migration, and invasion, while promoted cellular apoptosis in both U251 and U87. These results suggest that TUSC7 might act as a tumor suppressor and play a crucial role in the tumorigenesis of glioma.
Bioinformatics analysis is an effective tool to predict and validate the target genes of specific microRNAs, including lncRNAs. In this study, TUSC7 mRNA was a potential target of miR-23b following computational analysis using Targetscan, Starbase and microRNA.org. Gain and loss functions were used to confirm TUSC7 as a direct and specific target of miR23b. First, miR-23b expression was up-regulated significantly in glioma, and its effect on U251 and U87 was consistent with Chen's report (Chen et al., 2012) . TUSC7 expression was negatively correlated with the expression of miR-23b in glioma. Second, the luciferase reporter assay and RNA pull-down assay strongly validated the sequence-specific and direct combination between miR-23b and TUSC7. Finally, loss-and gain-of-function genetic approaches involving miR23b negatively regulated the expression of TUSC7 in U251 and U87 cells. Conversely, TUSC7 also significantly negatively regulated miR-23b expression in glioma U251 and U87 cells. Reversed pull-down assay confirmed the specific and direct combination between miR-23b and TUSC7. These results indicated a reciprocal inhibition between miR-23b and TUSC7 in glioma. We elucidated the underlying mechanism of the miRNA/lncRNA trans-regulatory function via RIP with antiAgo2 antibody. The results support the role of RISC in the reciprocal repression, which is consistent with our previous studies. LncRNA CASC2 was another tumor suppressing gene in glioma, which suppressed the malignant behavior of glioma largely by inhibiting miR-21 in RISC complex (Wang P. et al., 2015) .
Based on the evidence suggesting that TUSC7 regulated the biological behavior of glioma cells via reciprocal inhibition between miR-23b and TUSC7, we hypothesized that TUSC7 acted by directly silencing miR-23b expression. In order to test our hypothesis, agomir-23b was transfected into TUSC7-overexpressing glioma cells and found that miR-23b enhancement clearly promoted the malignant behavior of glioma cells. Further, the regulatory effects of TUSC7 on cells were reversed by partially up-regulating miR-23b, supporting our hypothesis significantly.
In summary, decreased expression of TUSC7 is a prognostic biomarker associated with poor prognosis in glioma patients. TUSC7 was targeted and inhibited reciprocally by miR-23b, and acted as a tumor-suppressing gene, which inhibited the malignant behavior of glioma cells. Our study facilitated the understandings of TUSC7 function in gliomagenesis, and provided a novel therapeutic target.
